Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECT204 T-Cell Therapy in Advanced Hepatocellular Carcinoma
NCT04864054Phase 2Recruiting
- Sponsor
- Eureka Therapeutics, Inc.
- Start
- Mar 2022
- Primary completion
- Dec 2027
- Modality
- TCR-Engineered T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of ECT204 in hepatocellular carcinoma (HCC), sponsored by Eureka Therapeutics, Inc.. Started Mar 2022; status: recruiting.
02
Drugs
ECT204
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04864054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864054.